The dual-inhibition of TIM-3 and PD-1 shows significant anti-tumor effectiveness compared to monotherapy in the HCC xenograft mouse model [37], and enhances the anti-tumor effectiveness of oncolytic virotherapy compared to single blockade in lung cancer [38]. Here, HAVCR2 is linked to hepatocellular carcinoma.